Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Foresight Diagnostics | 2024 | Series B | $33.0M | Denver |
| Spear Bio | 2024 | Series A | $45.0M | Weston |
| Cerevance | 2024 | Series B | $47.0M | Boston |
| Xaira Therapeutics | 2024 | Series A | $1.0B | South San Francisco |
| Cullinan Therapeutics | 2024 | Post Ipo Equity | $280.0M | Cambridge |
| Obsidian Therapeutics | 2024 | Series C | $160.5M | Cambridge |
| ImmPACT Bio | 2024 | Grant | $8.0M | Camarillo |
| Keros Therapeutics | 2024 | Post Ipo Equity | $140.0M | Lexington |
| Remix Therapeutics | 2024 | Series Unknown | $60.0M | Cambridge |
| Generation Bio | 2023 | Post Ipo Equity | $76.0M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Foresight Diagnostics | Series B | $33.0M | Denver, United States |
| 52 | Spear Bio | Series A | $45.0M | Weston, United States |
| 53 | Cerevance | Series B | $47.0M | Boston, United States |
| 54 | Xaira Therapeutics | Series A | $1.0B | South San Francisco, United States |
| 55 | Cullinan Therapeutics | Post Ipo Equity | $280.0M | Cambridge, United States |
| 56 | Obsidian Therapeutics | Series C | $160.5M | Cambridge, United States |
| 57 | ImmPACT Bio | Grant | $8.0M | Camarillo, United States |
| 58 | Keros Therapeutics | Post Ipo Equity | $140.0M | Lexington, United States |
| 59 | Remix Therapeutics | Series Unknown | $60.0M | Cambridge, United States |
| 60 | Generation Bio | Post Ipo Equity | $76.0M | Cambridge, United States |
Foresight Diagnostics develops novel technology for detect cancers from a simple blood draw.
Spear Bio is a biotech company that focuses on the detection of ultrasensitive protein.
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.
Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.
Inscripta is a life science technology company that develops digital genome engineering solutions.
Mindstrong is a virtual mental health platform.
Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries.
Cue is a healthcare technology company that enables people to manage their health through actionable and connected health data.
Velia is a biotech company that discovers and develops the therapeutic potential of human proteins.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.
Tasso is a Medical innovation company changing the way diagnostics are delivered
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Tesseract Health provides devices for disease monitoring and prevention.
Theseus Pharmaceuticals is a technology-based company.
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
EverlyWell is a digital health company that offers consumer testing, virtual care, at-home collection tests, and digital results.
Kira Pharmaceuticals is a Biotechnology Research Company.
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Foresite Capital has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Foresite Capital's top investment sectors include Biotechnology, Health Care, Life Science, Therapeutics, Pharmaceutical. The firm invests across 23 different industry categories.
Among tracked funding rounds, Xaira Therapeutics received $1.0B in a Series A round. Foresite Capital's total known invested capital is $8.3B.
Foresite Capital's average investment size is $127.9M across its portfolio of 81 companies.
Recent Foresite Capital portfolio additions include Foresight Diagnostics, Spear Bio, Cerevance, Xaira Therapeutics, Cullinan Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors